¼¼°èÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå
CRISPR and Cas Genes
»óǰÄÚµå : 1791598
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 174 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

¼¼°èÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº 2030³â±îÁö 132¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 51¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â CRISPR ¹× Cas À¯ÀüÀÚ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 17.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 132¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠŰƮ ¹× ½Ã¾àÀº CAGR 19.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 42¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶óÀ̺귯¸® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 18.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 13¾ï ´Þ·¯, Áß±¹Àº CAGR 16.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº 2024³â¿¡ 13¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 20¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.3%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 16.2%¿Í 14.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 12.6%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

CRISPR ±â¼úÀÌ »ý¸í°øÇп¡ Çõ¸íÀ» ÀÏÀ¸Å°´Â ÀÌÀ¯´Â ¹«¾ùÀϱî? À¯ÀüÀÚ ÆíÁýÀÇ ºÎ»ó ޱ¸

¼¼°è CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº À¯Àü°øÇÐ, »ýÀÇÇÐ ¿¬±¸, ³ó¾÷ »ý¸í°øÇÐÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î ÀÎÇØ ±Þ°ÝÇÑ ¼ºÀåÀ» °ÅµìÇϰí ÀÖ½À´Ï´Ù. CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) ±â¼úÀº Àü·Ê ¾ø´Â Á¤È®¼º°ú È¿À²¼ºÀ¸·Î Á¤¹ÐÇÑ À¯ÀüÀÚ ÆíÁýÀ» °¡´ÉÇÏ°Ô Çϴ ȹ±âÀûÀÎ µµ±¸·Î µîÀåÇß½À´Ï´Ù. À¯ÀüÁúȯ, ¾Ï, Èñ±ÍÁúȯ Ä¡·á¸¦ À§ÇÑ À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ CRISPR ±â¹Ý ¿ëµµ¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ó¾÷ »ý¸í°øÇÐ ±â¾÷µéÀº CRISPRÀ» ÀÛ¹° °³·®, ³»º´¼º, ½Äǰ »ý»ê È¿À²¼º Çâ»óÀ» À§ÇØ È°¿ëÇϰí ÀÖ½À´Ï´Ù. ÇÕ¼º»ý¹°ÇÐ ºÐ¾ßÀÇ È®´ë¿Í ¸ÂÃãÀÇ·áÀÇ ¹ßÀüÀº ½ÃÀå ¼ö¿ä¸¦ ´õ¿í °­È­Çϰí ÀÖÀ¸¸ç, CRISPRÀº Ç¥Àû À¯ÀüÀÚ º¯Çü¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀ» ¼±µµÇÏ´Â CRISPR ÀÀ¿ë ºÐ¾ß´Â? ÁÖ¿ä ºÎ¹®º° ºÐ¼®

½ÃÀå ¼¼ºÐÈ­´Â ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß·Î ¼¼ºÐÈ­µÇ¾î ÀÖÀ¸¸ç, °¢ ÀÀ¿ë ºÐ¾ß´Â ƯÁ¤ °úÇÐ ¹× ÀÇ·á ¹ßÀü¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù. À¯ÀüÀÚ Ä¡·á´Â ¿©ÀüÈ÷ °¡Àå À¯¸ÁÇÑ ÀÀ¿ë ºÐ¾ß Áß ÇϳªÀ̸ç, CRISPRÀº °â»ó ÀûÇ÷±¸ ºóÇ÷ ¹× ³¶Æ÷¼º ¼¶À¯Áõ°ú °°Àº À¯Àü¼º ÁúȯÀ» À¯¹ßÇÏ´Â À¯ÀüÀÚ µ¹¿¬º¯À̸¦ ±³Á¤ÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ³ó¾÷ »ý¸í°øÇеµ Áß¿äÇÑ ºÐ¾ß Áß ÇϳªÀ̸ç, CRISPRÀº °¡¹³ ÀúÇ×¼º, ³»º´¼º, ¿µ¾ç°¡ °­È­·Î ÀÛ¹° °³¹ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. CRISPR ±â¹Ý Áø´ÜÀÇ ºÎ»óµµ ƯÈ÷ Äڷγª19¸¦ Æ÷ÇÔÇÑ °¨¿°¼º ÁúȯÀÇ °ËÃâ¿¡ °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å¾à °³¹ß ºÐ¾ß¿¡¼­´Â À¯ÀüÀÚ Á¶ÀÛ ¼¼Æ÷ ¸ðµ¨À» »ý¼ºÇÏ´Â CRISPRÀÇ ´É·ÂÀ¸·Î ÀÎÇØ ÀǾàǰ ¿¬±¸ ¹× °³¹ßÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÇÕ¼º»ý¹°ÇÐ ¹× »ê¾÷ ÀÀ¿ëÀ» À§ÇÑ CRISPR ±â¹Ý ¹ÙÀÌ¿À Á¦Á¶ ¼Ö·ç¼ÇÀÇ °³¹ßÀº ½ÃÀå ±âȸ¸¦ ´õ¿í ´Ù¾çÈ­Çϰí ÀÖ½À´Ï´Ù.

Çõ½ÅÀº ¾î¶»°Ô CRISPR ½ÃÀåÀ» ÁÖµµÇϰí Àִ°¡: AI, ÀÚµ¿È­, À±¸®Àû °í·ÁÀÇ ¿ªÇÒ

CRISPR ½ÃÀåÀº AI¸¦ Ȱ¿ëÇÑ À¯ÀüÀÚ ÆíÁý, À¯ÀüÀÚ ½ºÅ©¸®´× ÀÚµ¿È­, À¯Àüü º¯ÇüÀÇ À±¸®Àû Áøº¸ µî ²÷ÀÓ¾ø´Â Çõ½ÅÀ¸·Î ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ »ý¹°Á¤º¸ÇÐ µµ±¸´Â CRISPRÀÇ È¿À²¼ºÀ» ³ôÀ̰í, ¿¬±¸ÀÚµéÀÌ ¿ÀÇÁŸ°Ù È¿°ú¸¦ ¿¹ÃøÇϰí, À¯ÀüÀÚ ÆíÁýÀÇ Á¤È®µµ¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Cas12, Cas13 µî Â÷¼¼´ë Cas ´Ü¹éÁúÀÇ °³¹ß·Î CRISPRÀÇ ¹ü¿ë¼ºÀÌ È®´ëµÇ¾î RNA ±â¹Ý º¯Çü ¹× ƯÀ̼º Çâ»óÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ·Îº¿ ½ÇÇè½Ç ½Ã½ºÅÛÀ» ÅëÇÑ CRISPR ¿öÅ©Ç÷οìÀÇ ÀÚµ¿È­´Â ¿¬±¸ »ý»ê¼ºÀ» °¡¼ÓÈ­Çϰí, ¼öÀÛ¾÷ °³ÀÔÀ» ÁÙÀ̸ç, 󸮷®À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ÆíÁý, ƯÈ÷ Àΰ£ »ý½Ä¼¼Æ÷ °è¿­ÀÇ º¯ÇüÀ» µÑ·¯½Ñ À±¸®Àû Á¶»ç´Â Ã¥ÀÓ ÀÖ´Â ¿¬±¸ °üÇàÀ» º¸ÀåÇϱâ À§ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í »ý¸íÀ±¸®¿¡ ´ëÇÑ ³íÀǸ¦ Ã˹ßÇϰí ÀÖ½À´Ï´Ù. DNA ¿°±â¼­¿­À» º¯°æÇÏÁö ¾Ê°í À¯ÀüÀÚ ¹ßÇöÀ» ±³Á¤ÇÏ´Â CRISPR ±â¹Ý ÈļºÀ¯ÀüÇÐÀû ÆíÁýÀÇ µîÀåÀº º¹ÀâÇÑ Áúº´ Ä¡·á¿¡ »õ·Î¿î °¡´É¼ºÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù.

CRISPR ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡? ÁÖ¿ä ½ÃÀå ¿µÇâ¿äÀο¡ ´ëÇÑ ¼³¸í

CRISPR ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÏ´Â °ÍÀº À¯ÀüÀÚ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀÇ·á ¹× ³ó¾÷ ºÐ¾ß·ÎÀÇ Àû¿ë È®´ë, Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀÔ´Ï´Ù. Á¤¹Ð ÀÇÇÐÀÇ ºÎ»óÀº CRISPR ±â¹Ý Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ¿© À¯Àü¼º Áúȯ ¹× ¾Ï¿¡ ´ëÇÑ °³ÀÎ ¸ÂÃãÇü Ä¡·á ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ ÀçÁ¤Àû Áö¿ø°ú ÇмúÀû ¿¬±¸ ³ë·ÂÀ¸·Î CRISPR ±â¹Ý ½Å¾à °³¹ß ¹× Áúº´ ¸ðµ¨¸µÀÇ Çõ½ÅÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ±âÈÄ º¯È­¿¡ °­ÇÑ ÀÛ¹°¿¡ ´ëÇÑ ³ó¾÷ ºÎ¹® ¼ö¿ä Áõ°¡´Â CRISPRÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇÏ¿© ½Ä·® ¾Èº¸ ¹®Á¦¿¡ ´ëÇÑ Áö¼Ó °¡´ÉÇÑ ÇØ°áÃ¥À» Á¦°øÇÕ´Ï´Ù. »ý¸í°øÇÐ ½ºÅ¸Æ®¾÷ÀÇ È®´ë¿Í Á¦¾à»ç¿Í ¿¬±¸±â°üÀÇ Á¦ÈÞ´Â ½ÃÀå °æÀï·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª À±¸®Àû Ãø¸é°ú ±ÔÁ¦Àû Ãø¸é¿¡ ´ëÇÑ °í·Á´Â ¿©ÀüÈ÷ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, CRISPRÀÇ »ó¿ëÈ­ ¼Óµµ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ °úÇÐÀû Çõ½Å°ú ÁøÈ­ÇÏ´Â ±ÔÁ¦ ȯ°æÀ¸·Î ÀÎÇØ ¼¼°è CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº À¯Àü°øÇÐ ¹× °³ÀθÂÃãÇü ÇコÄÉ¾î ºÐ¾ß¿¡¼­ »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÖ¸ç Çõ½ÅÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç°£¦¼­ºñ½º(ŰƮ ¹× ½Ã¾à, ¶óÀ̺귯¸®, µðÀÚÀÎ Åø, Ç×ü, ¼¼Æ÷ÁÖ °øÇÐ, gRNA µðÀÚÀÎ ¹× ÇÕ¼º, ½ºÅ©¸®´× ¼­ºñ½º), ¿ëµµ(¹ÙÀÌ¿À ÀÇ·á ¿ëµµ, ³ó¾÷ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹× Á¦¾à ±â¾÷ ÃÖÁ¾ ¿ëµµ, Çмú ¹× Á¤ºÎ ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ¼öŹ ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global CRISPR and Cas Genes Market to Reach US$13.2 Billion by 2030

The global market for CRISPR and Cas Genes estimated at US$5.1 Billion in the year 2024, is expected to reach US$13.2 Billion by 2030, growing at a CAGR of 17.4% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 19.0% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Libraries segment is estimated at 18.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 16.3% CAGR

The CRISPR and Cas Genes market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.2% and 14.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global CRISPR and Cas Genes Market - Key Trends & Drivers Summarized

Why Is CRISPR Technology Revolutionizing Biotechnology? Exploring the Rise of Gene Editing

The global CRISPR and Cas genes market has seen exponential growth, driven by groundbreaking advancements in genetic engineering, biomedical research, and agricultural biotechnology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a game-changing tool, enabling precise gene editing with unprecedented accuracy and efficiency. The increasing focus on gene therapy for treating genetic disorders, cancer, and rare diseases has propelled investment in CRISPR-based applications. Additionally, agricultural biotechnology firms are leveraging CRISPR for crop improvement, disease resistance, and enhanced food production efficiency. The expanding field of synthetic biology and the development of personalized medicine have further strengthened market demand, with CRISPR playing a crucial role in targeted genetic modifications.

Which CRISPR Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR and Cas genes market is segmented into various applications, each catering to specific scientific and medical advancements. Gene therapy remains one of the most promising applications, with CRISPR being used to correct genetic mutations responsible for inherited disorders such as sickle cell anemia and cystic fibrosis. Agricultural biotechnology is another key segment, where CRISPR is revolutionizing crop development by enhancing drought resistance, disease tolerance, and nutritional content. The rise of CRISPR-based diagnostics has also gained traction, particularly in detecting infectious diseases, including COVID-19. Additionally, the field of drug discovery is benefiting from CRISPR’s ability to create genetically engineered cell models, improving pharmaceutical research and development. The development of CRISPR-based biomanufacturing solutions for synthetic biology and industrial applications has further diversified market opportunities.

How Is Innovation Driving the CRISPR Market? The Role of AI, Automation & Ethical Considerations

The CRISPR market is evolving rapidly with continuous innovations in AI-powered gene editing, automation in genetic screening, and ethical advancements in genome modification. AI-driven bioinformatics tools have enhanced CRISPR efficiency, enabling researchers to predict off-target effects and optimize gene-editing accuracy. The development of next-generation Cas proteins, such as Cas12 and Cas13, has expanded CRISPR’s versatility, allowing for RNA-based modifications and improved specificity. Additionally, the automation of CRISPR workflows through robotic lab systems has accelerated research productivity, reducing manual intervention and increasing throughput. Ethical considerations surrounding gene editing, particularly in human germline modifications, have prompted regulatory frameworks and bioethical discussions to ensure responsible research practices. The emergence of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR Market? Key Market Influencers Explained

The growth in the CRISPR and Cas genes market is driven by increasing investment in genetic research, expanding applications in medicine and agriculture, and continuous technological advancements. The rise of precision medicine has fueled demand for CRISPR-based therapies, offering personalized treatment solutions for genetic disorders and cancer. Additionally, government funding and academic research initiatives have accelerated innovation in CRISPR-based drug discovery and disease modeling. The agricultural sector’s growing need for climate-resilient crops has further boosted CRISPR adoption, providing sustainable solutions for food security challenges. The expansion of biotech startups and partnerships between pharmaceutical companies and research institutions has strengthened market competitiveness. However, ethical and regulatory considerations remain a critical factor, influencing the pace of CRISPR commercialization. With ongoing scientific breakthroughs and evolving regulatory landscapes, the global CRISPR and Cas genes market is expected to witness transformative growth, unlocking new possibilities in genetic engineering and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the CRISPR and Cas Genes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis, Screening Services); Application (Biomedical Application, Agricultural Application); End-Use (Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â